Similar to SSc patients, Fra-2 TG mice have high levels of inflammatory mediators such as IL-1β and IL-6, and of Th2 cytokines such as IL-4 and IL-13 [1, 2, 17, 20], thus representing a valuable model to test drug candidates for SSc-ILD patients. This evidence concerns the gene IL1B and systemic sclerosis.